Tianjin, China, October 15, 2020
CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX:06185) announced today that it has signed an advance purchase agreement with the Mexico government, aims to provide Mexico with 35 million doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV"). In addition, the Mexican authority has also entered partnership with AstraZeneca PLC, Pfizer Inc., and the COVAX, which enables a total number of 116 million local people to be vaccinated.
According to the agreement, CanSinoBIO will supply 35 million doses of COVID-19 vaccine to Mexico from the end of 2020 to the year of 2021. Ad5-nCoV is the only single-dose regime candidate among the ones that Mexican authority purchased, which means CanSinoBIO is capable of meeting the needs of 35 million Mexicans in regards to this collaboration.
Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, stated: “The safety and quality of our vaccine candidate have not only been verified in the phase I and II clinical results, but also have been recognized by the health authorities of many countries. We will continue to advance the large-scale clinical study forward, meanwhile expanding the manufacturing capacity to ensure the accessibility of the vaccine, especially for the unserved and underserved regions and population."
The Ad5-nCoV, jointly developed by CanSinoBIO and Beijing Institute of Biotechnology (BIB), Academy of Military Medical Sciences, became the first of its kind that has entered the clinical development in March 2020. It is also the first candidate that has published the positive results of the phase I and II clinical studies on the Lancet. The data has demonstrated that a single-dose injection of the candidate can induce a balanced humoral and cellular immune response. Currently, there’s no severe side effects occurred among volunteers. In June, the candidate received the Military Specially-needed Drug Approval. In August, it became the first COVID-19 vaccine candidate in China to be patented.
October 8th, China has officially joined the COVAX, meaning that China will be in full support of equal global access to the COVID-19 vaccine. Ad5-nCoV is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform. It uses the replication-defective adenovirus type 5 as the vector to express the SARS-CoV-2 spike protein, which avoids the biosafety risks. The vaccine remains stable between 2°C and 8°C, making it easier for transportation and storage. This technology has already been successfully applied to the Ad5-EBOV, which is the only Ebola vaccine product approved for emergency use and national stockpiling in 2017.
In alignment with the goal of COVAX, CanSinoBIO has been actively expanding manufacturing capacity through building new facility that meets the domestic and international GMP standards, as well as seeking partners worldwide for large-scale production of the vaccine.
Incorporated in 2009, CanSinoBIO (SHSE: 688185, HKEX:06185) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine approved in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).